Venetoclax
NPM1 Mutation
Kura Oncology, Inc.Small moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the NPM1 Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Shen yang | Phase 3 | BB |
Azacitidine Shen yang | Phase 2 | B |
Daunorubicin Shen yang | Phase 2 | B |
BN104 Institut de Recherches Internationales Servier (I.R.I.S.) | Phase 1/2 | CC |
Same molecule, other indications
Venetoclax is also rated in:
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →